PTAB upholds Lialda patent's validity

The Patent Trial and Appeal Board of the U.S. Patent and Trademark Office upheld the validity of the only Orange Book-listed patent for ulcerative colitis drug Lialda mesalamine from Shire plc (LSE:SHP; NASDAQ:SHPG).

PTAB evaluated an inter partes review (IPR) petition from Kyle Bass' Coalition for Affordable Drugs challenging U.S. Patent No. 6,773,720, which covers controlled-release oral compositions containing 5-aminosalicylate (5-ASA) (see BioCentury Extra, Oct. 16, 2015). ...